This is according to new research presented at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting by Elizabeth McDonald, a professor of radiology in Penns Perelman School of Medicine and a practicing breast radiologist at Penns Abramson Cancer Center
The FDA in the United States has issued warnings about contamination and dosing inconsistencies in compounded GLP-1 products, and Health Canada has echoed similar concerns
[10] In the SURMOUNT-1 trial, patients with obesity achieved average weight reductions of approximately 15-21% of body weight over 72 weeks, alongside improvements in cardiovascular risk factors including blood pressure and lipid profiles, though cardiovascular outcome benefits have not yet been established
Andersson A, Brattstrm L, Israelsson B, Isaksson A, Hamfelt A, and Hultberg B (1992)
The nuclear factor erythroid 2related factor 2 (Nrf2) was assessed using ELISA technique, kit No